Assessment of Failures of Long-acting Cabotegravir and Rilpivirine in a Real-world Treatment Setting

2025/06/14 by Nicholas Yared, Smitha Gudipati, Shannon R. Payne +1 · 1 voice
Medicine · #HIV/AIDS drug development and treatment #Hepatitis B Virus Studies #Hepatitis C virus research

paper · pdf · doi:10.1093/ofid/ofaf349

openalex publication_date 2025/06/14 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/30

Abstract

Fifty-eight people with HIV switched to long-acting cabotegravir and rilpivirine in a real-world clinic setting had higher discontinuation rates because of virologic failure, side effects, or nonadherence compared to clinical trials. Archived proviral genotype testing before long-active cabotegravir and rilpivirine switch should be considered to reduce virologic failure risk.

Citations

• Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
• Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis

Discussions

• Assessment of Failures of Long-Acting Cabotegravir and Rilpivirine in a Real-World Treatment Setting ✅ Just Accepted #IDSky [bsky, 0 points, 0 comments]

Related

• Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
• Sustained HIV Viral Suppression 18 Months After the Last Dose of Long-acting Cabotegravir/Rilpivirine: A Case Report
• Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis
• Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters
• Clinical Outcomes and Perspectives of People With Human Immunodeficiency Virus Type 1 Twelve Months After Initiation of Long-acting Cabotegravir and Rilpivirine in an Observational Real-world US Study (BEYOND)